- Home
- LCTX vs REE Comparison
LCTX vs REE Comparison
Compare LCTX & REE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- REE
- Stock Information
- Founded
- LCTX 1990
- REE 2011
- Country
- LCTX United States
- REE Israel
- Employees
- LCTX N/A
- REE N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- REE Auto Manufacturing
- Sector
- LCTX Health Care
- REE Consumer Discretionary
- Exchange
- LCTX Nasdaq
- REE Nasdaq
- Market Cap
- LCTX 95.2M
- REE 77.3M
- IPO Year
- LCTX N/A
- REE N/A
- Fundamental
- Price
- LCTX $0.49
- REE $0.85
- Analyst Decision
- LCTX Strong Buy
- REE Strong Buy
- Analyst Count
- LCTX 5
- REE 3
- Target Price
- LCTX $4.20
- REE $12.50
- AVG Volume (30 Days)
- LCTX 860.2K
- REE 526.4K
- Earning Date
- LCTX 05-13-2025
- REE 05-15-2025
- Dividend Yield
- LCTX N/A
- REE N/A
- EPS Growth
- LCTX N/A
- REE N/A
- EPS
- LCTX N/A
- REE N/A
- Revenue
- LCTX $9,557,000.00
- REE $183,000.00
- Revenue This Year
- LCTX N/A
- REE $18,412.57
- Revenue Next Year
- LCTX $232.66
- REE $938.14
- P/E Ratio
- LCTX N/A
- REE N/A
- Revenue Growth
- LCTX 19.42
- REE N/A
- 52 Week Low
- LCTX $0.37
- REE $2.31
- 52 Week High
- LCTX $1.40
- REE $11.72
- Technical
- Relative Strength Index (RSI)
- LCTX 54.19
- REE 24.37
- Support Level
- LCTX $0.45
- REE $2.68
- Resistance Level
- LCTX $0.49
- REE $3.61
- Average True Range (ATR)
- LCTX 0.03
- REE 0.35
- MACD
- LCTX 0.00
- REE -0.12
- Stochastic Oscillator
- LCTX 72.25
- REE 1.43
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is developing REEcorner technology which packs critical vehicle components into a single compact module positioned between the chassis and the wheel as well as building commercial Electric Vehicles (EV) leveraging REEcorner technology. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.